Targeting SUN2 for Neurodegenerative Disorders (G25777)

Target Name: SUN2

NCBI ID: G25777

SUN2

Targeting SUN2 for Neurodegenerative Disorders

SUN2 (SUN domain-containing protein 2 (isoform 2)) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the superfamily of N-cadherin subfamily A, which includes proteins that are involved in cell-cell adhesion. SUN2 is one of the isoforms of the protein, and it has been shown to play a role in a variety of physiological processes in the body.

Disease association

SUN2 is closely associated with a number of diseases, including neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. These disorders are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to contribute to the symptoms associated with these disorders.

One of the mechanisms that has been proposed to explain the association between SUN2 and neurodegenerative disorders is the role that the protein plays in the development and progression of these disorders. For example, studies have shown that individuals with the genetic mutation that is associated with the neurodegenerative disorder, APTXN3, have reduced levels of SUN2 in their brain. Additionally, experiments have shown that manipulating the levels of SUN2 in brain cells has been effective in reducing the symptoms of neurodegenerative disorders.

Another potential mechanism that may contribute to the association between SUN2 and neurodegenerative disorders is the role that the protein plays in the regulation of cellular processes that are important for brain function. For example, studies have shown that SUN2 is involved in the regulation of the formation and stability of blood-brain barrier cells, which are responsible for controlling the movement of substances into and out of the brain. Additionally, the protein has been shown to play a role in the regulation of neurotransmitter release from neurons, which is important for brain function.

The potential therapeutic benefits of targeting SUN2

The association between SUN2 and neurodegenerative disorders makes it an attractive target for therapeutic intervention. Targeting the protein with drugs or other therapeutic agents that can modulate its levels or activity could potentially lead to the development of treatments for neurodegenerative disorders.

One approach that has been explored for targeting SUN2 is the use of small molecules that can modulate the activity of the protein. For example, a class of drugs called N-terminal hypervariable regions (NHRs) have been shown to be effective in modulating the activity of SUN2. These drugs work by binding to a specific region of the protein that is located at the N-terminus, where the protein is involved in its interactions with other proteins.

Another approach that has been explored for targeting SUN2 is the use of antibodies that can selectively bind to the protein. These antibodies are designed to recognize a specific epitope (a region of the protein that is unique to one isoform) of the protein, and can be used to label the protein for study or to block its activity in certain cellular processes.

Current research and clinical trials

While there is currently no cure for neurodegenerative disorders, there are a number of treatments that are available that can help manage the symptoms. However, there is a need for new and more effective treatments for these disorders, particularly those that can specifically target the mechanisms that are involved in their development and progression.

Targeting SUN2 is an promising approach for the development of new treatments for neurodegenerative disorders. While more research is needed to fully understand the role that the protein plays in these disorders and the potential benefits of targeting it, studies have shown that manipulating the levels of SUN2 in brain cells has been effective in reducing the symptoms of neurodegenerative disorders. Additionally, the use of small molecules and antibodies that can modulate the activity of SUN2 is an attractive approach for targeting the protein and potentially developing treatments for neurodegenerative disorders.

Conclusion

SUN2 (SUN domain-containing protein 2 (isoform 2)) is a protein that is involved in a variety of physiological processes in the body, including the regulation of cell

Protein Name: Sad1 And UNC84 Domain Containing 2

Functions: As a component of the LINC (LInker of Nucleoskeleton and Cytoskeleton) complex, involved in the connection between the nuclear lamina and the cytoskeleton. The nucleocytoplasmic interactions established by the LINC complex play an important role in the transmission of mechanical forces across the nuclear envelope and in nuclear movement and positioning. Specifically, SYNE2 and SUN2 assemble in arrays of transmembrane actin-associated nuclear (TAN) lines which are bound to F-actin cables and couple the nucleus to retrograde actin flow during actin-dependent nuclear movement. Required for interkinetic nuclear migration (INM) and essential for nucleokinesis and centrosome-nucleus coupling during radial neuronal migration in the cerebral cortex and during glial migration. Required for nuclear migration in retinal photoreceptor progenitors implicating association with cytoplasmic dynein-dynactin and kinesin motor complexes, and probably B-type lamins; SUN1 and SUN2 seem to act redundantly. The SUN1/2:KASH5 LINC complex couples telomeres to microtubules during meiosis; SUN1 and SUN2 seem to act at least partial redundantly. Anchors chromosome movement in the prophase of meiosis and is involved in selective gene expression of coding and non-coding RNAs needed for gametogenesis. Required for telomere attachment to nuclear envelope and gametogenesis. May also function on endocytic vesicles as a receptor for RAB5-GDP and participate in the activation of RAB5

The "SUN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SUN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets